Lilly Asks High Court To Review Double Patenting
Eli Lilly & Co. has petitioned the U.S. Supreme Court to review the Federal Circuit's ruling that the drugmaker's patent for cancer treatment Gemzar was invalid for double patenting, saying the...To view the full article, register now.
Already a subscriber? Click here to view full article